Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 8/20 | 0.55 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948234 | 0.85 | IL4I1 (0.65) | IL4I1SCD5SCDRXFP1POLB | |
| SCHEMBL30948132 | 0.83 | IL4I1 (0.68) | IL4I1SCD5SCDRXFP1POLB | |
| SCHEMBL30948130 | 0.80 | IL4I1 (0.63) | IL4I1RXFP1TP53 | |
| SCHEMBL27163401 | 0.79 | IL4I1 (0.52) | IL4I1HSD11B1GRM5RXFP1TP53 | |
| SCHEMBL30947975 | 0.79 | IL4I1 (0.67) | IL4I1HSD11B1GRM5RXFP1TP53 | |
| SCHEMBL30948099 | 0.78 | IL4I1 (0.49) | IL4I1HSD11B1GRM5RXFP1TP53 | |
| SCHEMBL30948267 | 0.77 | IL4I1 (0.63) | IL4I1HSD11B1GRM5RXFP1TP53 | |
| SCHEMBL30948088 | 0.76 | IL4I1 (0.40) | IL4I1SCD5SCDCXCR1 | |
| SCHEMBL27163414 | 0.75 | IL4I1 (0.57) | IL4I1HSD11B1GRM5RXFP1TP53 | |
| SCHEMBL30948133 | 0.75 | IL4I1 (0.74) | IL4I1SCD5SCDGRM5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022227015-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885SCD5 4879/4885SCD 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.